AAV Ocular Gene Therapy for Sustained Anti-VEGF Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular angiogenic diseases such as wet age-related macular degeneration and diabetic retinopathy require frequent intravitreal injections, posing a burden on patients and caregivers, and real-world efficacy is often inferior to clinical trial results.
Innovation Solution
Compositions comprising nucleic acids encoding anti-angiogenic polypeptides like aflibercept and interfering RNA molecules targeting pro-angiogenic genes, delivered via adeno-associated virus vectors, to inhibit vascular endothelial growth factor (VEGF) signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If repeated intravitreal injections of anti-VEGF protein therapies are administered to maintain vision, then therapeutic efficacy is improved, but treatment burden on patients and caregivers increases substantially
Solution Approach 1:
The patent employs self-complementary AAV vectors that can transduce and express therapeutic genes autonomously in retinal cells, enabling the tissue to produce its own anti-angiogenic factors continuously without requiring repeated external injections. This self-sustaining expression mechanism directly reduces treatment burden while maintaining therapeutic efficacy.
Solution Approach 2:
The patent uses AAV-mediated gene delivery to establish permanent or long-lasting expression of anti-VEGF proteins and interfering RNAs in retinal cells before disease progression occurs or as a single upfront intervention. This preliminary genetic modification eliminates the need for subsequent repeated injections, addressing both the efficacy and treatment burden contradiction.
2Duration of action of moving object
If frequent intravitreal injections are required to maintain visual acuity benefit, then sustained anti-angiogenic activity is achieved, but patient compliance and real-world efficacy decrease
Solution Approach 1:
By enabling retinal cells to autonomously produce anti-angiogenic therapeutics through integrated gene therapy, the system ensures continuous drug production regardless of patient compliance issues. This self-sustaining mechanism extends the duration of action from weeks to potentially years, directly improving real-world efficacy by eliminating adherence barriers.
Solution Approach 2:
The patent achieves continuous anti-angiogenic activity through permanent or long-term expression of therapeutic genes in retinal cells. The AAV vectors integrate into the genome or maintain stable episomal expression, ensuring uninterrupted production of anti-VEGF proteins and interfering RNAs, thereby maintaining therapeutic effect without the gaps that occur with intermittent injections.
3Ease of operation
If single nucleic acid therapies are used to reduce injection frequency, then treatment burden is reduced, but sustained therapeutic effect may be insufficient compared to combination therapies
Solution Approach 1:
The patent combines multiple therapeutic mechanisms into a single AAV vector construct: overexpression of anti-VEGF proteins (such as aflibercept), expression of interfering RNAs to suppress VEGF mRNA, and use of self-complementary AAV for enhanced transduction efficiency. This merged combination therapy is delivered as a single injection, reducing treatment burden while achieving sustained therapeutic effects through multiple concurrent mechanisms.
Solution Approach 2:
The patent creates a composite therapeutic system within a single AAV vector that integrates multiple functional elements: promoter regions for constitutive expression, coding sequences for anti-VEGF proteins, interfering RNA sequences, and regulatory elements. This composite genetic construct enables simultaneous multiple mechanisms of action from a single administration, addressing both reduced injection frequency and sustained efficacy.
Data Source
Figure 1A~1B
Figure 2
Figure 3A~3B
AI summary
The present disclosure provides compositions and methods for the treatment of ocular diseases associated with angiogenesis, particularly wet age-related macular degeneration.